Cargando…
Correction to: Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma
Autores principales: | Jang, Sekwon, Poretta, Tayla, Bhagnani, Tarun, Harshaw, Qing, Burke, Matthew, Rao, Sumati |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477051/ https://www.ncbi.nlm.nih.gov/pubmed/32683664 http://dx.doi.org/10.1007/s13555-020-00422-7 |
Ejemplares similares
-
Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma
por: Jang, Sekwon, et al.
Publicado: (2020) -
Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
por: Samlowski, Wolfram, et al.
Publicado: (2022) -
Adherence to Adjuvant Therapy in Patients with Resected Melanoma: An Application of the Theory of Planned Behavior
por: Beisel, Cassie, et al.
Publicado: (2022) -
Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival
por: Weber, Jeffrey S., et al.
Publicado: (2022) -
Correction to: Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival
por: Weber, Jeffrey S., et al.
Publicado: (2022)